Literature DB >> 80224

Maternal plasma alpha-fetoprotein screening for fetal neural tube defects.

D J Brock, J B Scrimgeour, J Steven, L Barron, M Watt.   

Abstract

Maternal plasma alpha-fetoprotein (AFP) screening for fetal neural tube defects (NTD) was used as a part of routine antenatal care in three hospitals over a 26 month period. Blood samples were obtained for plasma AFP measurement at 15 to 20 weeks gestation from 6377 women, representing 79 per cent of antenatal bookings. The outcome of pregnancy was ascertained in 96 per cent of patients: 13 cases of anencephaly and 7 of open spina bifida were detected by plasma screening and a further 3 cases of open NTD through the mother's previous medical history and amniotic fluid determination. Four fetuses with open NTDs and four with closed NTDS were not detected by plasma AFP measurement and the detection efficiency for open NTDs was thus 83 per cent. Integration of screening into the existing pattern of antenatal care required only minor alterations in clinic schedules. Some extra time was needed for explanation of the objectives of the study, for ultrasound examination and for amniocentesis. Eight patients declined the offer of a plasma test, while only one refused an amniocentesis.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 80224     DOI: 10.1111/j.1471-0528.1978.tb14923.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  11 in total

1.  Population screening for cystic fibrosis.

Authors:  D Brock
Journal:  Am J Hum Genet       Date:  1990-07       Impact factor: 11.025

2.  Maternal serum alpha-fetoprotein screening for neural tube defects. Report of a combined study in Germany and short overview on screening in populations with low birth prevalence of neural tube defects.

Authors:  W Fuhrmann; H K Weitzel
Journal:  Hum Genet       Date:  1985       Impact factor: 4.132

3.  Maternal serum alpha-fetoprotein screening: report of a Canadian pilot project.

Authors:  T A Doran; G H Valentine; P Y Wong; G Wielgosz; R J Benzie; H C Soltan; M R Jenner; P A Morland; R J Montgomery; L C Allen
Journal:  CMAJ       Date:  1987-08-15       Impact factor: 8.262

4.  Prenatal fetal karyotyping and maternal serum alpha-fetoprotein screening.

Authors:  C Gosden; K Buckton; Z Fotheringham; D J Brock
Journal:  Br Med J (Clin Res Ed)       Date:  1981-01-24

5.  Ethnic differences in the distribution of congenital malformations.

Authors:  P B Terry; P M Mathew; R G Condie; J G Bissenden
Journal:  Postgrad Med J       Date:  1983-10       Impact factor: 2.401

6.  Maternal alpha fetoprotein screening.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1981-10-17

7.  Impact of maternal serum alpha-fetoprotein screening on antenatal diagnosis.

Authors:  D J Brock
Journal:  Br Med J (Clin Res Ed)       Date:  1982-07-31

Review 8.  A research framework for evaluating the promotion of mental health and prevention of mental illness.

Authors:  L Eisenberg
Journal:  Public Health Rep       Date:  1981 Jan-Feb       Impact factor: 2.792

9.  Amniotic fluid and maternal serum amino acid levels in malformations of fetal central nervous system.

Authors:  S Kumar; J R Foreman; M Rathi
Journal:  Neurochem Res       Date:  1980-04       Impact factor: 3.996

10.  Maternal alpha-fetoprotein screening: two years' experience in a low-risk district.

Authors:  S J Standing; M J Brindle; A P Macdonald; R W Lacey
Journal:  Br Med J (Clin Res Ed)       Date:  1981-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.